Phase I trial evaluating the safety and efficacy of DAR 901 in BCG-vaccinated, HIV-positive adults
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2014
Price : $35 *
At a glance
- Drugs IMM-201 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 21 Mar 2014 New trial record
- 19 Mar 2014 Planned initiation date changed from 1 Dec 2013 to 1 May 2014, based on information from Dartmouth's Geisel School of Medicine and Aeras.
- 19 Mar 2014 Status changed from planning to not yet recruiting, according to Dartmouth's Geisel School of Medicine and Aeras.